

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 2 of 4	Application Number	10/738,413
	Filing Date	December 17, 2003
	First Named Inventor	Binetti, R.
	Art Unit	1635
	Examiner Name	Bowman, Amy Hudson
	Attorney Docket Number	SC66U-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		BOONANUNTANASARN et al., Specific gene silencing using small interfering RNAs in fish embryos, 2003, Biochemical and Biophysical Research Communications, 310, page 1089-1095.	
		CAPLEN et al., dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference, 2000, Gene, 252, pages 95-105.	
		ZHANG et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, 5, pages 1-7.	
		HARTMANN et al., Hypopigmentary skin disorders: current treatment options and future directions, 2004, Drugs, 64(1), pages 89-107.	
		POLLARK, Andrew, Method of Turn Off Bad Genes Is Set for Tests on Human Eyes	
		VAN DE Water et al., Intravenously administered siRNA accumulates in the kidney, Am Soc for Pharm and Experimental Therapeutics, 2006.	
		XIE et al., Harnessing in vivo siRNA delivery for drug discovery and therapeutic development, 2006, Drug Discovery Today, Vol 11, No. 1/2, pages 67-73.	
		ZIMMERMANN et al., RNAi-mediated gene silencing in non-human primates, 2006, Nature Publishing Group, Vol 4414, pages 111-114.	
		MORRIS, Therapeutic potential of siRNA-mediated transcriptional gene silencing, April 2006, Therapeutic Applications of RNAi, page 7-13.	
↓		GAUR, RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases, April 2006, Therapeutic Applications of RNAi, page 15-22.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
---------------------------	--------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/738,413
Filing Date	December 17, 2003
First Named Inventor	Binetti, R.
Art Unit	1635
Examiner Name	Bowman, Amy Hudson
Attorney Docket Number	SC66U-US

Sheet

3

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		ROSSI, RNAi as a treatment for HIV-1 infection, April 2006, Therapeutic Applications fo RNAi, pages 25-29.	
		RONDINONE, Therapeutic potential of RNAi in metabolic diseases, April 2006, Therapeutic Applications fo RNAi, pages 31-36.	
		BROWN et al., Toward silencing the burden of malaria: progress and prospects for RNAi-based approaches, April 2006, Therapeutic Applications fo RNAi, pages 38-44.	
		MARQUES et al., Activation of the mammalian immune system by siRNAs, 2005, Nature Biotechnology, Vol 23, No. 11, pages 1399-1405.	
		PUSHPARAJ et al., Short interfering RNA (siRNA) as a novel therapeutic, 2006, Clinical and Experimental Pharm and Physiology ,33, p. 504-510.	
		DYKXHOORN et al., Running Interference: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule Drugs, 2006, Annu. Rev. Biomed. Eng., 8:15.1-15.26.	
		BRUMMELKAMP et al., A System for Stable Expression of Short Interfering RNAs in Mammalian Cells, 2002, Science, 296: 550-553.	
		ELBASHIR et al., Effective expression of small interfering RNA in human cells, 2001, Nature, 411: 494-498.	
		PAUL et. al., Effective expression of small interfering RNA in human cells, 2002, Nature Biotech., 20:505-508.	
↓		HANNON, G., RNA interference, 2002, Nature, 418: 244-251.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/738,413
		Filing Date	December 17, 2003
		First Named Inventor	Binetti, R.
		Art Unit	1635
		Examiner Name	Bowman, Amy Hudson
		Attorney Docket Number	SC66U-US
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		CAPLEN, et al., Specific inhibition of gene expression by samll double-stranded RNA in invertebrate and vertebrate systems, 2001, Proc Natl Acad Sci USA, 98:9742-9747.	
		ELBASHIR, et al., Functional anataomy of siRNAsfor mediating effecient RNAi in Drosophila melanogaster embryo lysate, 2001, European Molecular Bio Org Journal, 20:6877-88.	
		JARVIS et al., siRNA-Mediated Grne Silencing in Mamalian Cells, 2002, Ambion, Inc., poster published on the world wide web at ambion.com/techlib/posters/RNAi_0302.html.	
		ROZEMA, D. and Lewis, D., siRna delivery technologies for mammalian systems, 2003, Targets, 2: 253-260.	
		DAVIS S.S. and Walker I.M., Multiple Emulsions as Targetable Delivery Systems, 1987, Methods in Enzymology, 149:51-64.	
		MAYHEW E. et al., High-Pressure Continuous-Flow System for Drug Entrapment in Liposomes, 1987, Methods in Enzymology, 149:64-77.	
		SHAHER-KORTING M. et al., Liposome preparations: A step forward intopical drug therapy for skin disease?, 1989, J. Am. Acad. Dermatol., 21:1271-1275.	
✓		FLEISCHER et al., The combination of 2% 4-hydroxyanisole (Mequinol)...., J. Am Acad. Dermatol. 2000, vol 42(3): 459-467.	

Examiner Signature	/Amy Bowman/	Date Considered	03/20/2007
---------------------------	--------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.